CTT Pharma's CEO Issues Letter to Shareholders

Rhea-AI Summary

CTT Pharmaceutical Holdings (OTCQB:CTTH) CEO Ryan Khouri provided a shareholder update regarding the company's ongoing grant applications and smoking cessation initiatives. The company has submitted applications for NIH and NSF grants before the January 6th deadline, with responses expected in April or May 2025. The review process is scheduled to begin in March.

The NIH grant would enable Johns Hopkins University to conduct clinical trials of CTT's innovative smoke-free low dose dissolvable strip, potentially creating the first new oral smoking cessation product in 40 years. The company has strengthened its team by adding two experienced grant specialists.

Khouri previously spoke at the FDA Headquarters in Maryland in October 2024 at an FDA and NIH event on Advancing Smoking Cessation Technology, receiving positive feedback. A conference call with shareholders is planned for April 2025, with the specific date to be announced.

Positive

• Potential NIH grant could enable clinical trials at prestigious Johns Hopkins University
• Development of first new oral smoking cessation product in 40 years
• Added two experienced grant specialists to strengthen application process
• Presented at FDA Headquarters with positive feedback

Negative

• Grant approval remains uncertain
• Clinical trials haven't started yet, pending grant approval

TAMPA, FL / ACCESS Newswire / March 12, 2025 / CTT Pharmaceutical Holdings, Inc. (OTCQB:CTTH)

Dear Shareholders,

I wanted to issue this brief letter to share a few updates. To start, it's important to note that there are no delays with the NIH or NSF grants. These grants were filed in advance of the January 6^th deadline and as a result we are expecting answers in May possibly April. I also received notification that the review process for these grants will start in March. The NIH grant would allow Johns Hopkins University the ability to move forward with clinical trials of our smoke-free low dose dissolvable strip and allow CTT to create the first oral smoking cessation product in 40 years. Additionally, we added two people to the company to help with the NIH and NSF grants. They have extensive knowledge about our technology and have many years of experience with grants. I'm hopeful that the time is now for the government to step in and help us advance the fight against cigarette smoking as smoking kills over 8 million people around the world every year. The CDC states the following, "Cigarette smoking is a major public health concern, with over 16 million Americans living with a smoking related disease. Smoking harms nearly every organ of the body and is the leading preventable cause of disease, death, and disability in the United States causing more than 480,000 deaths each year in the United States." I spoke in October of 2024 at the FDA Headquarters in Maryland about Advancing Smoking Cessation Technology that was held by the FDA and NIH. I received a tremendous amount of positive feedback and look forward to speaking again about CTT in the near future. In April, I will do a conference call and will notify shareholders soon of a specific date.

Ryan Khouri, CEO of CTT Pharma

Contact Information:
CTT Pharma - 813-606-0060

SOURCE: CTT Pharmaceutical Holdings, Inc.

View the original press release on ACCESS Newswire

FAQ

When will CTT Pharma (CTTH) receive responses for their NIH and NSF grant applications?

CTT Pharma expects to receive responses in April or May 2025, with the review process starting in March 2025.

What is CTT Pharma's (CTTH) innovative smoking cessation product under development?

CTT is developing a smoke-free low dose dissolvable strip, which could become the first new oral smoking cessation product in 40 years.

Which institution will conduct clinical trials for CTT Pharma's (CTTH) smoking cessation product?

Johns Hopkins University will conduct the clinical trials if the NIH grant is approved.

When is CTT Pharma's (CTTH) next shareholder conference call scheduled?

A conference call is planned for April 2025, with the specific date to be announced.